NeoGenomics, Inc. (FRA:NG9)
10.40
+0.10 (0.97%)
Last updated: Dec 5, 2025, 8:04 AM CET
NeoGenomics Revenue
NeoGenomics had revenue of $187.80M USD in the quarter ending September 30, 2025, with 11.90% growth. This brings the company's revenue in the last twelve months to $709.16M, up 10.10% year-over-year. In the year 2024, NeoGenomics had annual revenue of $660.57M with 11.65% growth.
Revenue (ttm)
$709.16M
Revenue Growth
+10.10%
P/S Ratio
2.19
Revenue / Employee
$322.35K
Employees
2,200
Market Cap
1.32B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 660.57M | 68.92M | 11.65% |
| Dec 31, 2023 | 591.64M | 81.92M | 16.07% |
| Dec 31, 2022 | 509.73M | 25.40M | 5.24% |
| Dec 31, 2021 | 484.33M | 39.88M | 8.97% |
| Dec 31, 2020 | 444.45M | 35.62M | 8.71% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Rheinmetall AG | 11.00B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
NeoGenomics News
- 21 days ago - Neo Performance Materials Inc. (NEO:CA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - NeoGenomics to Participate in Upcoming Investor Conferences - Business Wire
- 5 weeks ago - NeoGenomics Inc (NEO) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... - GuruFocus
- 5 weeks ago - NeoGenomics (NEO) Showcases Advancements in Liquid Biopsy Technology - GuruFocus
- 5 weeks ago - NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors - Business Wire
- 5 weeks ago - NeoGenomics (NEO) Q3 2025 Earnings Call Transcript - The Motley Fool
- 5 weeks ago - NeoGenomics outlines $30B MRD market pursuit and reiterates 2025 growth targets amid record clinical revenue - Seeking Alpha
- 5 weeks ago - NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript - Seeking Alpha